OTC : GRPOF

Investor PresentationMay 2, 2017

CSE: TBPOTC: GRPOF

OTC : GRPOF

Forward Looking Statements

This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties.Actual events or results could differ materially from the expectations and projections of Tetra Bio-Pharma Inc. The informationcontained in this presentation has not been approved or disapproved by any Securities Commission in Canada, The Securities andExchange Commission in the US or other regulatory body. Except for statements of historical fact relating to the Company, certaininformation contained herein constitutes "forward-looking statements". Forward-looking statements are frequently characterizedby words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certainevents or conditions "may" or "will" occur.

Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, andare subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materiallyfrom those projected in the forward-looking statements. These factors include the inherent risks involved in the development ofbotanical based pharmaceuticals or medical devices regulated by Health Canada, the FDA or other international regulatoryagencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated withproduct approvals in multiple jurisdictions.

The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs offinancing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The readeris cautioned not to place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation toupdate or revise publicly any forward-looking statements, whether as a result of new information, future event or otherwise, afterthe date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of ourrepresentatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of theinformation in this presentation.

Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise,to you or any person resulting from the use of the information in this presentation by you or any of your representatives orfrom omissions from the information in this presentation.

1

OTC : GRPOF

Tetra Bio-Pharma is a bio-pharmaceutical company focused on cannabis

Tetra implements a vertically integrated approach to the development production

and distribution of plant based pharmaceuticals and Bio health products and

supplements with a focus on cannabinoid research and product development

Company Snapshot

▪ Tetra Founded: 2015

▪ CSE (TBP) CAD$0.69

▪ OTCQB (GRPOF) US$0.51

▪ Market Capitalization CAD$79M

▪ Shares Issued 115M

▪ Shares Fully Diluted 131M

▪ Insider Ownership 9.4%

▪ Cash/Equivalent (As of April 28, 2017) CAD$2.8M

▪ Cash Burn Rate/Month CAD$100K

▪ Employees 8

2

OTC : GRPOF

Innovations in Pharmaceutical Cannabis & Nutraceuticals

Pharmaceutical development of

Cannabis-based drug products

Commercialization of Cannabis-

based products for the cosmetic

and supplement markets

License application in system.

Land kept for an interested

partner

3

OTC : GRPOF

REPORT: The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020Viridian Capital Advisors | Wednesday, 02 December 2015 05:43 (EST)

4

OTC : GRPOF

THE PHARMACEUTICAL APPROACH TO CANNABIS RESEARCH AND MEDICAL INNOVATION

A Physician’s decision to prescribe a new drug or even a natural health product has to bebased on Evidence-Based Medicine – A legal and ethical requirement

▪Currently, no body of evidence exists to not support the prescription or recommendation of medicalmarijuana in any medical condition, including terminal cancer. According to Canadian and USA drugregulatory agencies, the is no evidence to support the safety and efficacy of marijuana for use inthe treatment of pain or any other indication.

▪TBP product development plan would provide the data necessary for drug regulatory agencies to grantmarketing approval and physicians to prescribe or recommend our products.

▪As cannabis becomes legalised across the globe the medical and scientific community would stillrequire pharmaceutical consumer drug products developed with proper research , data and protocol.Insurance companies will only be able to cover the cost of products with Drug Identification Numbers.

▪TBP takes the natural aspects of medical cannabis and applies the science of pharma to developproducts that patients want , doctors want to prescribe and insurance companies will cover.

5

OTC : GRPOF

Tetra’s Product PipelineTetra invests significant time and capital into a continuous and sustainable pipe lineof products based on patient needs and driven by scientific R&D

6

OTC : GRPOF

Prescription Drugs

▪ PPP001:

▪ Bringing ‘smoked’ marijuana to patients

▪ PPP002:

▪ Adjunct therapy for Breakthrough Cancer Pain

▪ PPP003:

▪ Monotherapy and Combination product – oral administration

▪ Chronic pain, PTSD and other neurologic and psychiatric conditions

▪ PPTGR:

▪ Topical prescription drug for pain management

▪ R&D*

▪ To generate pipeline (create IP and disease-specific treatments)

7

OTC : GRPOF

▪ Develop and commercialize Cannabis-derived products for the consumer market

▪ NSERC funded Partnership with McGill University

▪ Target the USA and Canadian retail markets:

– Generate revenues from product sales in the Food, dietary supplement and cosmetic markets

– Launch THC and CBD-free extracts of Cannabis in 2017

– Readiness to commercialize THC and CBD containing products in Canada when legalization is effective

Partnership #2: Bringing Cannabis-based Products to Retail Markets

8

OTC : GRPOF

▪ Co-Development with acquisition of technology if successful Phase II in patients

▪ Advantage over approved synthetic THC:

▪ Significant reduction of side effects in patients and stability at room temperature

▪ Phase I completed:

▪ Demonstrated that safety will be significantly superior

Partnership #3 (PPP002): Co-Development – Sustained Release of THC

9

OTC : GRPOF

▪ Significantly increase potential to develop pipeline with strong IP

▪ AgroTek Health will launch a product approved by NNHPD that induces the CB1 receptor to relieve pain

▪ Replace the PPTGR technology (Topical pain relief) with this technology (THC and CBD containing topical drug). Pursue original development plan. IP protection for technology.

▪ Discovery stage R&D that will lead to new patented THC and CBD based therapies

Partnership #4: Investment & Acquisition of R&D Stage Biotech

10

OTC : GRPOF

GOAL OF PARTNERSHIP #5 (PPP003)

▪ Co-Development and commercialization of botanical combination (herb-Cannabis) products: ▪ A partnership defined by a contractual agreement▪ A Joint Venture (JV) owned 50-50 by 3rd Partnership and TBP

▪ PPP003 is the combination of extracts of –hypnotic herb and Cannabis oil (extract or further refining of oil) ▪ Two track development:

▪ Cannabis oil as a monotherapy for anxiety and insomnia▪ Combination product for same indications

▪ Therapeutic targets: ▪ Neurological, mental, psychiatric conditions (e.g., anxiety,

reduced intake of antipsychotics, PTSD, insomnia)▪ Psychiatrist already proactive using cannabis to lower doses

of antipsychotic drugs or sleep and anxiety drugs (SSRI)

11

OTC : GRPOF

Partners

Algorithme Pharma is conducting stage 1 clinical trials of PP001 in collaboration with Phyto Pain Pharma

McGill University is collaborating with AgroTek and Grow Pros on an NSERC funded research study to develop consumer products containing cannabinoids

Aphria is a publicaly traded producer of Medicinal Cannabis under license from the Canadian Federal Government Aphria has partnered with Tetra for the production of Cannabis for use in PPP001

The National Sciences and Engineering Research Council of Canada connects industry with world-firsts in knowledge and the people behind them, fueling R&D and leading to firsts in the marketplace. They have granted TBP subsidiary Grow Pros Cannabis with research funding related to the development of Consumer products in collaboration with the university of McGill

12

OTC : GRPOF

Cannabis / Medicinal Plantcultivation and sourcing

▪ Originally applied for ACMPR license in November of 2014, Currently in stage 3/5

▪ Owns a lease option on 190 acres of agricultural land 45 min north of Ottawa

▪ Signed a co-op agreement with Delta 9 Bio tech to collaborate onlicensing of the facility

▪ Currently examining alternative licensing options for Pharma Development andsourcing legal supply for use in Pharma and NHP products

13

OTC : GRPOF

Competitive Landscape

GW Pharma $GWPH Market Capitalization: $3.0B USD

GW Pharma has 2 products in its pipe line in stage 1 and stage 3 for epilepsy and MS

Cannabis Science Inc. $CBIS Market Capitalization $171M USD Conducts qualitative research on medicinal cannabis in a non pharmaceutical manor. They have no products in Clinical Testing

INSYS Therapeutics inc- $INSYMarket Capitalization $811M USD

Is a traditional Pharma company that was awarded organ drug status for CBD for treatment of GBM. They do not have any current clinical trials

Zynerba Pharmaceuticals $ZYNE-Market Capitalization $278M USD

Developing a synthetic THC transdermal patch as well as a synthetic CBD gel

Cara Therapeutics Inc. $CARA Market Capitalization $505M USD

R&D on Cannabinoid preceptors . Utilizing synthetic compounds

14

OTC : GRPOF

Current Market Valuation ~79M

Value Total

Common Shares 114.5 M

Warrants exp 09/28/18 0.07 - 0.26 8.7 M

Compensation Warrants 0.05 4.0 M

OPTIONS exp 11/5/17 0.05 - 0.18 3.8 M

Average Price of Warrants: $0.20Average Price of Options: $0.21

Capital Structure (as of April 30, 2017)

15

OTC : GRPOF

Financing

▪ Jan 15 - Oct16Raised ~$1.4M through private placements and executedwarrants at .025-.05-.10-.15

▪ October 2016Secured 2M equity line of Credit from NYC private equity firmAlumina Partners

▪ November 2016Closed a $914,000 financing round at .15 with afull 12 month warrant at .20

▪ December 2016 ▪ $1M investment from Aphria @.20 with a .26 warrant forced exercise at

.45▪ Closed a $479,100 financing round at .20 with a

full 12 month warrant at .26

16

OTC : GRPOF

Leadership

Executive Team

▪ Andre Rancourt – Chief Executive Officer

▪ Guy Chamberland, PHD – Chief Scientific officer

▪ Sabino Di Paola – Chief Financial officer

▪ Ryan Brown – VP, Business Development

▪ Edward Miller – VP, IR & Corporate Communications

▪ Denis Courchesne – VP, Sales

▪ Randy Ringuette, PHD – Medical Researcher

▪ Charles Campbell, PHD – Medical Researcher

Board of Directors

▪ Andre Audet – Chairman/Director

▪ Andre Rancourt – Director

▪ Benoit Chotard – Director

▪ Robert Brouillette – Director

17

OTC : GRPOF

Contact

Edward Miller

VP, IR & Corporate Communications

edward@tetrabiopharma.com

www.tetrabiopharma.com

18